KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Accounts Payables (2018 - 2025)

Adaptive Biotechnologies' Accounts Payables history spans 8 years, with the latest figure at $6.5 million for Q4 2025.

  • For Q4 2025, Accounts Payables fell 10.98% year-over-year to $6.5 million; the TTM value through Dec 2025 reached $6.5 million, down 10.98%, while the annual FY2025 figure was $6.5 million, 10.98% down from the prior year.
  • Accounts Payables for Q4 2025 was $6.5 million at Adaptive Biotechnologies, down from $10.3 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $12.2 million in Q1 2024 and bottomed at $2.7 million in Q2 2022.
  • The 5-year median for Accounts Payables is $6.7 million (2025), against an average of $6.9 million.
  • The largest annual shift saw Accounts Payables tumbled 55.36% in 2022 before it soared 236.88% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $3.3 million in 2021, then surged by 144.45% to $8.1 million in 2022, then decreased by 4.52% to $7.7 million in 2023, then fell by 5.88% to $7.3 million in 2024, then decreased by 10.98% to $6.5 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Accounts Payables are $6.5 million (Q4 2025), $10.3 million (Q3 2025), and $6.9 million (Q2 2025).